^
    6ms
    TRIGGERCD8: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=194, Recruiting, L & L biopharma Co., Ltd., Shanghai China | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    LB1410 • LB4330
    6ms
    TRIGGERCD8: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=194, Not yet recruiting, L & L biopharma Co., Ltd., Shanghai China
    New P1/2 trial • Combination therapy • Metastases
    |
    LB1410 • LB4330
    9ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001） (clinicaltrials.gov)
    P1, N=66, Recruiting, L & L biopharma Co., Ltd., Shanghai China | Trial primary completion date: Sep 2026 --> Sep 2025
    Trial primary completion date • Metastases
    |
    LB4330
    over1year
    A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors. (ASCO 2023)
    Enrollment in cohort 1 began in Nov 2022. Clinical trial information: NCT05707676.
    Clinical • P1 data • PK/PD data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CLDN18 (Claudin 18) • CD8 (cluster of differentiation 8)
    |
    LB4330
    almost2years
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001） (clinicaltrials.gov)
    P1, N=66, Recruiting, L & L biopharma Co., Ltd., Shanghai China
    New P1 trial • Metastases
    |
    CLDN18 (Claudin 18)
    |
    LB4330